文献速递抗栓抗凝管理药物不良反应与药物警戒

口服抗凝治疗中的胃肠道出血:当前已知情况

Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known.
PubMed 文献 · Drug Saf · 2022-10-13

胃肠道出血是口服抗凝治疗中最常见的出血类型。随机对照试验的荟萃分析显示,直接口服抗凝药(DOACs)的胃肠道出血率高于华法林,但研究间异质性显著,且不同DOACs之间存在差异。观察性研究的荟萃分析表明,华法林与不同DOACs相比的胃肠道出血率高低不一。目前尚无直接比较单个DOACs的随机对照试验,最佳比较信息来自观察性研究,提示利伐沙班的胃肠道出血风险可能高于其他DOACs。口服抗凝药诱发的胃肠道出血可能有助于结直肠癌检测,且华法林可能降低癌症发生率。

要点

  • DOACs整体胃肠道出血率高于华法林,但阿哌沙班和低剂量达比加群与华法林相似。
  • 利伐沙班胃肠道出血风险可能高于其他DOACs,基于观察性研究证据。
  • 口服抗凝药可能促进结直肠癌检测,华法林可能降低癌症发生率。

核心结论

  • DOACs与华法林相比胃肠道出血率因药物和剂量而异,利伐沙班风险可能较高,且口服抗凝药可能有助于癌症检测。

研究设计与样本

  • 本文为综述,汇总了房颤患者关键随机对照试验的荟萃分析及观察性研究的荟萃分析结果。

主要发现

  • 随机对照试验荟萃分析显示DOACs胃肠道出血率高于华法林,但研究间异质性显著。
  • 利伐沙班、高剂量达比加群和高剂量艾多沙班胃肠道出血率高于华法林,而阿哌沙班和低剂量达比加群与华法林相似。
  • 观察性研究荟萃分析显示华法林胃肠道出血率低于利伐沙班、相似或低于达比加群、高于阿哌沙班。
  • 观察性研究提示利伐沙班胃肠道出血风险可能高于其他DOACs。
  • 口服抗凝药可能促进结直肠癌检测,华法林可能降低癌症发生率。

临床怎么用

  • 临床选择口服抗凝药时应考虑胃肠道出血风险差异,尤其对高风险患者。
  • 间接比较DOACs不可靠,需参考观察性研究证据个体化决策。

局限性

  • 无随机对照试验直接比较单个DOACs,间接比较因入选标准不同不可靠。
  • 观察性研究结果存在冲突,证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gastrointestinal bleeding (GIB) is the most common type of bleeding occurring in patients on oral anticoagulation. A meta-analysis of the landmark randomized controlled trials (RCTs) for patients with atrial fibrillation demonstrated that direct oral anticoagulants (DOACs) were associated with higher GIB rates compared to warfarin. However, significant heterogeneity existed between studies. While rivaroxaban, high-dose dabigatran, and high-dose edoxaban were associated with higher GIB rates than warfarin, GIB rates were similar between warfarin users and both apixaban and low-dose dabigatran users. Additionally, previous observational studies have yielded conflicting reports on whether GIB rates differ between warfarin and DOACs. Meta-analyses of observational studies demonstrated that warfarin is associated with lower rates of GIB compared to rivaroxaban, similar or lower rates compared to dabigatran, and higher rates compared to apixaban. Importantly, no RCT has compared individual DOACs directly and due to the different selection criteria of the initial RCTs, indirect comparisons between DOACs using these studies are unreliable. The best available information of comparisons between individual DOACs is therefore limited to observational studies. There is mounting evidence that suggests that rivaroxaban is associated with a higher risk of GIB compared to other DOACs. Finally, GIB induced by oral anticoagulation may have some positive aspects. Interestingly, there are studies that indicate oral anticoagulation facilitates colorectal cancer detection. Furthermore, results from RCTs and observational studies suggest that warfarin may even decrease the incidence of cancer.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Ingason AB, Hreinsson JP, Björnsson ES, et al. Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known. Drug Saf. 2022. PMID: 36227528. doi:10.1007/s40264-022-01243-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。